Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus JANUMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN AND LINAGLIPTIN versus JANUMET.
EMPAGLIFLOZIN AND LINAGLIPTIN vs JANUMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormones (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon levels.
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
10 mg empagliflozin / 5 mg linagliptin orally once daily
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
None Documented
None Documented
Empagliflozin: terminal half-life ~12.4 hours, allowing once-daily dosing. Linagliptin: terminal half-life ~113-131 hours due to saturable binding to DPP-4, enabling once-daily dosing despite short plasma half-life.
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
Empagliflozin: 54% excreted unchanged in urine (renal), 41% in feces (biliary/fecal). Linagliptin: 80% excreted unchanged in feces via enterohepatic circulation, <5% in urine.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor/Biguanide Combination